Introduction
B-cell chronic lymphocytic leukaemia (B-CLL) is a heterogenous disease with a highly variable clinical course. 1, 2 In a continuing effort to identify patients with poor prognosis and to facilitate the clinical management of B-CLL, several molecular prognostic markers have been identified during the last decade. Landmark studies by Hamblin et al. 3 and Damle et al. 4 have shown that the survival probability in B-CLL is associated with the absence or presence of somatic mutations in rearranged immunoglobulin heavy-chain variable (IgVH) genes. Currently, the IgVH gene mutation status is considered as one of the most powerful prognostic factors, 5 where B-CLL cases with unmutated IgVH genes are characterized by an unfavourable clinical outcome. However, IgVH mutation analysis is time consuming and technically demanding, thus limiting its use in clinical practice. Several DNA microarray studies comparing the transcriptomes of patient subgroups defined by the presence or absence of IgVH gene mutations [6] [7] [8] have identified genes that could be used as surrogate markers for the IgVH mutation status. One of these genes, the Syk-ZAP-70 protein tyrosine kinase family 70 kDa zeta-associated protein (ZAP-70) has recently been shown to play a role in B-cell receptor (BCR) signaling in IgVH-unmutated CLL cells. 9, 10 In addition, ZAP-70 protein expression can be conveniently measured by flow cytometry and a series of studies established ZAP-70 as a reliable prognostic marker, [11] [12] [13] possibly of even greater predictive value than IgVH mutation analysis. 14 Another surrogate marker for the mutated and unmutated IgVH B-CLL subgroups has been identified with the CD38 protein. 4 However, although vast numbers of subsequent studies could clearly demonstrate the clinical applicability of CD38 quantitation with some degree of correlation to IgVH mutation status, 4, 5, 13, [15] [16] [17] at present both parameters are regarded as independent prognostic variables in B-CLL. 5, 17 CD38 is a type II transmembrane glycoprotein that acts as a complex ectoenzyme and receptor molecule, which leads to enhancement of BCR signaling in B-CLL cells. 18, 19 Alike ZAP-70 detection, CD38 cell surface expression is amenable to routine flow cytometry and provides a valuable adjunct in the diagnostic work-up of B-CLL patients. 5, 16 Interestingly, coexpression of CD38 and ZAP-70 in B-CLL cells appears to correlate with a particularly strong BCR signaling capacity. 9, 10 Under the assumption that sustained BCR signaling in response to a yet unknown (auto)antigen may play an important role in B-CLL pathogenesis, we recently investigated in a cohort of 252 CLL patients whether CD38 can further refine the adverse prognostic relevance of high ZAP-70 expression levels. 13 In ZAP-70 þ CD38 þ B-CLL cases, median treatment-free survival was 30 months as compared to 130 months in patients with a ZAP-70 À CD38 À status. Discordant ZAP-70/CD38 resulted in a median treatment-free survival time of 43 months. Thus, ZAP-70 and CD38 expression analyses provided complementary prognostic information identifying three patient subgroups with good, intermediate and poor prognosis. 13 Aiming at molecular differences that may help explain the diverse clinical behaviour of B-CLL, the present study investigated cases at the extremes of the disease spectrum. A transcriptome analysis was performed on eight ZAP-70 þ CD38 þ vs eight ZAP-70 À CD38 À B-CLL samples employing the Affymetrix U133A platform. Supervised analysis revealed a panel of differentially expressed genes designated as 'B-CLL subtype distinction genes'. 7 Validation of these results was performed in a larger B-CLL patient cohort on a restricted panel of genes involved in BCR signaling, B-cell differentiation, angiogenesis and lymphomagenesis.
Patients, materials and methods

Patients
Peripheral blood samples from 94 patients with B-CLL were analysed after obtaining informed consent according to our institutional guidelines. The diagnosis of B-CLL required a persistent lymphocytosis of more than 5.0 Â 10 9 /l and a typical CD19
þ , Ig light chain (k or l light chain) restricted immunophenotype as revealed by flow cytometry of peripheral blood cells. Peripheral blood mononuclear cells (PBMCs) were isolated by Lymphoprep (Invitrogen, Karlsruhe, Germany) density-gradient centrifugation and cryopreserved until further analysis. Patient selection was based on the availability of frozen freshly isolated total RNA stored in our CLL cell bank and the previously determined expression status of ZAP-70 and CD38 (see below). Clinical and laboratory data of the study population are shown in Supplementary Table 1.
Gene expression profiling
Mononuclear cells were isolated from fresh peripheral blood samples as described. CD19-positive leukaemic B cells were enriched employing anti-CD19 magnetic microbeads (MidiMacs, Miltenyi Biotec, Bergisch Gladbach, Germany), resulting in a purity of 493% as determined by flow cytometry (Table 1) . Gene expression profiling was performed on total RNA extracted from 1 to 2 Â 10 8 CD19 þ cells (RNeasy Midi Kit, Qiagen, Hilden; Germany), using the Affymetrix U133A microarrays and GeneChip platform (Affymetrix, Santa Clara, CA, USA), as described recently. 13, 20 À patient samples at a false discovery rate of qp10% and defining a cutoff fold change of 72.0. Only genes called 'present' by the Affymetrix algorithm in at least 30% of either of the two groups were considered for SAM analysis. As CD19 purity and ZAP-70 expression levels showed some degree of variation (Table 1) , SAM analysis was also performed after excluding the lowest purity sample (i.e. CLL-12) and the samples closest to the ZAP-70 expression-defining margin (i.e. CLL-4 and CLL-15). Results are reported in Figure 1 and Supplementary Table 2 .
Real-time reverse transcriptase-polymerase chain reaction Total RNA from 1 to 2 Â 10 8 freshly isolated PBMC was extracted, purified (RNeasy Midi Kit) and quantified spectrophotometrically as described previously. 20, 22 The RNA isolation procedure included an on-column digestion step of residual genomic DNA using DNase I as recommended by the manufacturer in all samples analysed. First strand complementary DNA (cDNA) was synthesized from 1 mg of RNA using oligo(dT) primers employing a commercially available kit (RT-PCR Amplimers, Becton Dickinson, Heidelberg, Germany) according to the manufacturer's instructions, yielding a final cDNA volume of 100 ml. Real-time polymerase chain reaction (PCR) was performed with the ABI Prism 7900HT Sequence Detector (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions as described previously. 20, 22 PCR was carried out in a 20 ml reaction volume using 2 ml of cDNA with a Pim2-specific assay (Assays-on-demand Gene Table 1 Clinical and laboratory data of patients whose leukaemic cells were subjected to comparative microarray gene expression profiling 
(722.4)
Abbreviations: CLL, chronic lymphocytic leukaemia; FISH, fluorescence in situ hybridisation; F, female; M, male; ND, not determined.
Gene expression signatures separate B-CLL prognostic subgroups A Hüttmann et al expression system, Hs00179139_m1, Applied Biosystems). Target-specific primers were designed from sequences of exons 3 and 4 of the Pim2 gene. For normalization, the expression level of the housekeeping gene glycerolaldehyde-3-phosphate dehydrogenase (GAPDH) was measured as an endogenous control (Hs 99999905_m1, Applied Biosystems). For quantification of each PCR result, we calculated the DC t value between the target gene (Pim2) and its endogenous control (GAPDH). The mean DC t values of PBMC samples of five normal donors were then used as calibrators for relative quantification.
ZAP-70 expression
Cytoplasmic ZAP-70 expression was determined by flow cytometry as recently described. 12, 13 In brief, permeabilized cells were stained with anti-ZAP-70 (clone 2F3.2, Upstate Biotechnology, Waltham, MA, USA) as primary antibody and goat-anti-mouse immunoglobulin fluorescein isothiocyanate (FITC; Dako, Glostrup, Denmark) as secondary antibody. CD3-phycoerythrin (PE), CD56-PE (Becton Dickinson) and CD19-peridinin chlorophyll protein cytochrome 5.5 (Dako) were used for staining of T, natural killer and B lymphocytes, respectively. After appropriate lymphocyte gating, cytoplasmic ZAP-70 expression was determined in CD19 þ B-CLL cells as described. 12, 13 Data acquisition and analysis were performed using CellQuest software (Becton Dickinson).
CD38 expression
Fresh heparinized peripheral blood samples were prepared for flow cytometry by ammonium chloride erythrocyte lysis. As described previously, 13 the immunophenotype was characterized using the following panel of fluorochrome-labeled monoclonal antibodies using a standard three-colour flow cytometry approach:
To minimize potential contamination with coexisting normal B cells, only B-CLL cases in which 90% of CD19 þ CD20 þ cells coexpressed CD5 were included in the study.
Detection of genomic aberrations by fluorescence in situ hybridization
Prognostically relevant anomalies of chromosomal regions 11q, 13q, and 17p, and of chromosome 12 were assessed by fluorescence in situ hybridization, as described previously. 13 Evaluation of immune receptor translocation-associated protein 4/Fc receptor homologue 2 expression on CLL cells by flow cytometry
Immune receptor translocation-associated protein 4 (IRTA4)/Fc receptor homologue 2 (FcRH2) (also known as SPAP1) expression on the surface of B-CLL cells was determined by threecolour flow cytometry employing a combined direct/indirect staining technique using antibodies at pretested optimal concentrations. In brief, freshly thawed CLL-PBMC stored in dimethyl sulfoxide were stained with biotinylated anti-FcRH2/ IRTA4 (R&D Systems, Minneapolis, MN, USA) or an irrelevant IgG control antibody (Dako) as primary antibody and streptavidin-PE (R&D Systems) as secondary antibody in combination with directly labeled anti-CD5-FITC (Becton Dickinson) anti-CD19-PeCy5 (Dako). The relative density of IRTA4/FcRH2 on lymphocyte-gated CD19 þ /CD5 þ cells was quantified by determining the mean fluorescent intensity (MFI) for PE and subtracting the corresponding MFI values of the control antibody. Comparative experiments were performed on normal donor-derived PBMC (n ¼ 3) stained with biotinylated anti-IRTA4/FcRH2 (R&D Systems) followed by streptavidin-FITC (Dako) in combination with directly labeled anti-CD27-PE (R&D Systems) and anti-CD19PeCy5 (Dako). In these experiments, the relative density of IRTA4/FcRH2 on lymphocyte-gated CD19 þ CD27 À naive B cells was compared to that of CD19 þ CD27 þ memory B cells by determining the MFI for FITC and subtracting the corresponding MFI values of the control antibody.
Detection of proangiogenic factors in the blood plasma of CLL patients
Plasma was prepared from freshly collected heparinized peripheral blood samples and stored at À801C until analysis. Plasma levels of vascular endothelial growth factor (VEGF) and angiopoietin 2 (ANGPT2) were quantified using Quantikine solid phase enzyme-linked immunosorbent assays (ELISAs; R&D Systems). Table 1 showed differential regulation of 426 probe sets. These include 345 probe sets (encoding 292 genes) upregulated and 81 probe sets (encoding 66 genes) downregulated in ZAP-70 À CD38 À B-CLL cases (top, red circle to the left). When the sample with the lowest purity was excluded, 417 probe sets were differentially regulated (top, blue circle to the right). Out of these 417 probe sets, 361 were intersecting with the 'all samples' analysis. When cases with borderline ZAP-70 expression were excluded from the analysis (bottom, green circle), 325 probe sets were differentially regulated. The intersection between the three analyses leaves 250 differentially regulated probe sets encoding 210 genes at the core of the analysis. These 250 probe sets include all genes discussed in the present work, except for ANGPT2, which was found upregulated in both analyses at the top, but not in the analysis at the bottom where CLL-4 and CLL-15 were excluded. A detailed analysis of intersecting probe sets can be taken from Supplementary Table 2. Laboratories, Grand Island, NY, USA) with 10% (v/v) foetal calf serum (Greiner, Limburg, Germany) supplemented with 1000 U/ ml penicillin and 100 U/ml gentamycin (both from Sigma, Deisenhofen, Germany). After 3 days incubation in a 5% CO 2 and air incubator at 371C, cell culture supernatants were frozen at À801C until analysis for ANGPT2, as described above.
Cell cultures
Statistical analysis
Comparison of clinical or laboratory parameters between patient subgroups was performed using the non-parametric Mann-Whitney U-test or Kruskal-Wallis test for continuous variables and the w 2 test for categorical data. Differences were regarded significant at Po0.05. Retrieval of Gene-Ontology (GO) annotations and statistical analysis for significant (Po0.05) overrepresentation of individual annotations in the analysed list of genes was performed using GOstat (http://gostat.wehi. edu.au).
Results
Comparative gene expression analysis of ZAP-
Applying the filter and evaluation strategies detailed above SAM analysis revealed that a total of 292 genes (defined by 345 probe sets) were significantly upregulated in ZAP-70 þ CD38 þ as compared to the ZAP-70 À CD38 À B-CLL group. Conversely, 66 genes (defined by 81 probe sets) were significantly downregulated in the ZAP-70 þ CD38 þ B-CLL samples (Supplementary Table 3 ). The raw experimental data can be accessed through the internet (http://www.ncbi.nlm.nih.gov/geo/). Excluding the sample with the lowest CD19 purity or the samples closest to the ZAP-70 expression margin, left 210 genes (defined by 250 probe sets) at the core of the analysis (Figure 1) .
Of note, a substantial number of these 210 B-CLL subtype distinction genes including lipoprotein lipase (LPL), CRY1, ADAM29, TCF7, NRIP1, AKAP12 (gravin), DMD (dystrophin), TGFBR3, FGFR1, FUT8 and PTK2 have been described previously to be differentially expressed in microarray studies comparing B-CLL cases with the absence or presence of mutations in their IgVH genes. [6] [7] [8] To further elucidate, the biological processes and molecular pathways underlying the diverse clinical behaviour of the two patient subgroups the gene identifiers were linked to the GO database. 23 Pathways in the GO 'biological process' and 'molecular function' categories that showed significant enrichment for genes differentially expressed in ZAP-70 þ CD38 þ vs ZAP-70 À CD38 À B-CLL samples are listed in Supplementary Table 4 .
Selection of genes for confirmatory studies was based on (i) novelty, (ii) their potential functional relevance for the disease process and (iii) availability of reagents (antibodies/ELISA; fluorochrome-labeled DNA probes). As the number of CLL samples subjected to microarray analysis was small, we proceeded to validate three of the B-CLL subtype distinction genes (Supplementary (Figure 2a) . Interestingly, IRTA4/FcRH2 protein expression on normal donor-derived PB B-cells was significantly higher on CD19 þ CD27 þ memory as compared to CD19 þ CD27 À naive B cells (Figure 3a) .
Angiopoietin 2
To investigate the relation between ANGPT2 mRNA levels in B-CLL cells and protein secretion, we determined the concentration of ANGPT2 in plasma samples of 56 B-CLL patients (Figure 4 ) by ELISA. In line with the microarray experiments, we found a twofold increase of ANGPT2 plasma levels in the ZAP-70 þ CD38 þ as compared to the ZAP-70 À CD38 À patient subgroup. Furthermore, ANGPT2 plasma concentrations detected in Binet B and C patients exceeded those of Binet stage A patients suggesting that ANGPT2 protein secretion may be correlated to disease progression. In a cell culture experiment where five immunomagnetically purified B-CLL cases were studied, leucemic cells proved capable of secreting ANGPT2 into the culture supernatant in three cases (mean value 180 pg/ ml, range 70-255 pg/ml), thereby providing circumstantial evidence that the CLL cells are indeed the probable source of excess ANGPT2 protein production observed in the ZAP-70 þ CD38 þ patient cohort (Supplementary Table 5 ). As ANGPT2 may act synergistically with VEGF as a proangiogenetic stimulus in vivo we also measured the plasma concentrations of VEGF in 38 B-CLL individuals. As depicted in Figure 4 , ZAP-70 þ CD38 þ patients exhibited significantly higher VEGF plasma concentrations as compared to the ZAP-70 À CD38 À subgroup. In summary, these findings suggest a proangiogeneic phenotype for the ZAP-70 þ CD38 þ patient subgroup.
Pim2
The serine/threonine kinase Pim2 is a transcriptionally regulated oncogenic kinase that promotes cell survival by activating nuclear factor-kB (NF-kB)-dependent gene expression in response to a wide variety of proliferative signals. [27] [28] [29] Deregulation of Pim2 expression has been documented in several human malignancies including leukaemia, lymphoma and also B-CLL. [30] [31] [32] Pim2 mRNA expression was measured by real-time quantitative reverse transcriptase-PCR (RQ-PCR) in 94 patients using PBMC obtained from healthy individuals as a reference with an expression level of one. Overall, Pim2 was found to be expressed at 12-fold higher levels in B-CLL samples than in normal PBMC with a distribution range from 0.9 to 56.2 (data not shown). As inferred from the microarray experiments, Pim2 mRNA concentrations in ZAP-70 þ CD38 þ B-CLL samples were slightly higher than in the ZAP-70 À CD38 À samples ( Figure 5 , left part of panel a). However, this difference did not reach statistical significance if unfractionated PBMCs were used. Of note, there was a highly significant correlation between disease stage and Pim2 expression with Binet stage C exhibiting 1.8-fold higher Pim2 levels than Binet stage A samples ( Figure 5 , right part of panel a). We next compared Pim2 expression levels in unfractionated PBMCs, the CD3 þ and CD19 þ subset of normal donor and B-CLL samples (Figure 5b) . Taken together, a high proportion of non-CD19 þ cells may dilute Pim2 expression levels in unfractionated B-CLL samples with a low burden of leukaemic cells. If, in contrast to PBMCs, highly purified B-CLL samples from the favourable and unfavourable prognostic subgroups were tested for Pim2 expression (Figure 5c ), a significant difference with higher levels in the unfavourable subgroup became apparent. This finding suggests that Pim2 expression in B-CLL cells may be related to both disease stage and B-CLL subtype as defined by ZAP-70 and CD38 expression.
Discussion
Recent work has shown that measurement of ZAP-70 and CD38 expression on B-CLL cells by flow cytometry allowed for the separation of three patient subgroups with good (ZAP-70 À CD38 À ), intermediate (discordant expression of the two markers) and poor prognosis (ZAP-70 þ CD38 þ ). 13, 33 Following up on these observations, the present study investigated the transcriptomes of B-CLL cases at the extremes of the disease spectrum in order to identify molecular signatures underpinning the diverse clinical phenotypes. To this end eight ZAP-70 þ CD38 þ vs eight ZAP-70 À CD38 À B-CLL samples were analysed employing the Affymetrix U133A platform. Supervised analysis revealed a panel of 358 B-CLL subtype distinction genes, the majority of which (292 genes) was found to be overexpressed in the prognostically unfavourable ZAP-70 þ CD38 þ subgroup. Notably and reassuringly, despite the small sample size this list of differentially expressed genes showed a substantial overlap with results from previously published microarray studies comparing B-CLL cases with the absence or presence of mutations in their IgVH genes.
6-8 Among these distinction genes LPL, ADAM29, SPG20, NRIP1, AKAP12 and SEP10 have been attributed prognostic potential. 8, 34, 35 In a recent retrospective RQ-PCR study measuring mRNA transcript levels of LPL and ADAM29 in the leukaemic cells of 133 patients with B-CLL, 22 we (i) confirmed their value as independent prognostic variables and (ii) detected highly significantly different expression levels of both markers in ZAP-70 þ CD38 þ as compared to ZAP-70 À CD38 À B-CLL samples validating the microarray results presented herein. Comparative analysis of LPL and ADAM29 mRNA concentrations in patients for whom both microarray and RQ-PCR results were available, yielded concordant results (data not shown).
Distinct from previously published microarray studies, 6-8 the current study employed a patient selection approach based on ZAP-70 and CD38 quantitation. Both of these molecules can enhance BCR signaling, 9,10,18 thereby conveying an important prosurvival stimulus to the leukaemic cells which may partially explain the more aggressive clinical course of ZAP-70 þ CD38 þ B-CLL. 1, 9, 10, 18 Remarkably, the microarray experiments described herein revealed relative overexpression of additional BCR pathway components such as CD5, IGHD, IGL, IGLJ3 and IGLC2. These findings are in accordance with a recent flow cytometry study showing higher IgM surface levels on IgVH unmutated as compared to mutated B-CLL cells. 36 Furthermore, the present microarray analysis showed that FcRH2/IRTA4 was significantly downmodulated in ZAP-70 þ CD38 þ B-CLL, results which were subsequently confirmed at the protein level using flow cytometry in a series of 26 B-CLL patients. FcRH2/IRTA4 belongs to a recently recognized family of Ig domain containing type I membrane proteins, which exhibit sequence similarity to Fc receptors and are predominantly expressed in the B-cell compartment. 25, [37] [38] [39] It is currently unknown which ligands bind to this receptor family. The cytoplasmic segment of FcRH2/ IRTA4 contains a pair of typical immunoreceptor tyrosine-based inhibition motifs (ITIM). 26 These ITIM can be phosphorylated in response to receptor ligation and thereby recruit terminating SH2 domain containing phosphatases including SHP-1. As an anchor molecule of SHP-1, FcRH2/IRTA4 is believed to play an inhibitory role in BCR signaling. 26 The published in situ hybridization data suggest that FcRH2/IRTA4 RNA is predominantly expressed in naive B cells located in the mantle zone of the lymph follicle. 39 23 revealed significant enrichment of angiogenesis-related genes including ANGPT2 which was found to be overexpressed in the ZAP-70 þ CD38 þ CLL subgroup when all patients as listed in Table 1 were analysed. To further validate these results, we measured ANGPT2 concentrations in the plasma of 56 CLL patients. In accordance with the microarray experiments, we found a twofold increase of ANGPT2 plasma levels in the ZAP-70 þ CD38 þ as compared to the ZAP-70 À CD38 À patient subgroup. Furthermore, ANGPT2 plasma concentrations detected in Binet B and C patients exceeded those of Binet stage A patients suggesting that ANGPT2 protein secretion also may be correlated with disease progression. This observation is relevant in light of experiments showing that VEGF and basic fibroblast growth factor secreted by B-CLL cells induced bone marrow neoangiogenesis, [40] [41] [42] thereby adding to the maintenance of the leukaemic clone. As ANGPT2 acts in concert with VEGF as a proangiogenic stimulus, [43] [44] [45] we also measured VEGF plasma concentrations in our study population. Confirmatory of previously published studies, 40 VEGF plasma levels were found to be significantly increased in the ZAP-70 þ CD38 þ as compared to the ZAP-70 À CD38 À patient cohort. In another example of a non-solid malignancy, work by Loges et al. 46 hinted towards ANGPT2 mRNA expression levels in the leukaemic blasts of patients with newly diagnosed acute myeloid leukaemia as independent prognostic factor in this disease. This finding together with our observation of concordance between ANGPT2 and ZAP-70/CD38 expression status raises the possibility that ANGPT2 could also serve as a novel prognostic marker in B-CLL.
Potentially important, our analysis identified the serine/ threonine kinase Pim2 as another B-CLL subtype distinction gene that was found to be overexpressed in the ZAP-70 þ CD38 þ B-CLL cases. In line with data published by Cohen et al., 31 our RQ-PCR analysis in PBMCs from 94 CLL patients (and in 45 highly purified CLL samples) revealed significantly higher Pim2 expression levels in B-CLL cells as compared to normal donor-derived PBMCs. Pim2 mRNA concentrations in ZAP-70 þ CD38 þ B-CLL cells were significantly higher as compared to ZAP-70 À CD38 À samples when purified cells were tested. Also, we found a strong and statistically significant positive correlation of Pim2 expression with the Binet stage. This indicates that Pim2 may be upregulated in the more aggressive subgroup as well as in the course of the disease and therefore is a causative player in disease progression. Our results are confirmatory of findings in a series of 48 non-Hodgkin's lymphoma and B-CLL cases where a correlation of Pim2 expression levels in B-CLL cells with lymphocyte doubling time and Binet stage was reported and expand these to a larger patient cohort. 31 Pim2 functions as an inhibitor of apoptosis and is transcriptionally regulated by a variety of proliferative signals, promoting cell survival by inducing NF-kB-dependent gene expression. 27 Acting synergistically with CMYC and NMYC in generating T-and B-cell lymphomas, the precise role of Pim2 in lymphomagenesis remains to be elucidated. [28] [29] [30] [31] [32] Thus, based on the data initially reported by Cohen et al. 31 and the results presented herein Pim2 could serve as a promising target for the development of a novel treatment strategy in B-CLL.
